The comparative efficacy and safety of basiliximab and antithymocyte globulin in deceased donor kidney transplantation: a multicenter cohort study
暂无分享,去创建一个
B. Chung | Chul-woo Yang | W. Park | K. Jin | Seungyeup Han | Young Soo Kim | S. Hong
[1] M. Giral,et al. Induction therapy in kidney transplant recipients: Description of the practices according to the calendar period from the French multicentric DIVAT cohort , 2020, PloS one.
[2] C. Ahn,et al. Outcomes of kidney transplantation from elderly deceased donors of a Korean registry , 2020, PloS one.
[3] Kyunga Kim,et al. Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation , 2020, Journal of clinical medicine.
[4] J. Dantal,et al. Induction Therapy in Elderly Kidney Transplant Recipients With Low Immunological Risk , 2020, Transplantation.
[5] J. Park,et al. Comparison of clinical outcomes of deceased donor kidney transplantations, with a focus on three induction therapies , 2019, Korean journal of transplantation.
[6] R. Fabreti-Oliveira,et al. Effects of immunotherapy induction on outcome and graft survival of kidney-transplanted patients with different immunological risk of rejection , 2019, BMC Nephrology.
[7] Y. Oh,et al. Factors affecting mortality during the waiting time for kidney transplantation: A nationwide population-based cohort study using the Korean Network for Organ Sharing (KONOS) database , 2019, PloS one.
[8] J. Yang,et al. Factors Associated With Waiting Time to Deceased Donor Kidney Transplantation in Transplant Candidates. , 2018, Transplantation proceedings.
[9] P. Rosenbaum,et al. Comparing Outcomes between Antibody Induction Therapies in Kidney Transplantation. , 2017, Journal of the American Society of Nephrology : JASN.
[10] D. Abramowicz,et al. Induction Therapy for Kidney Transplant Recipients: Do We Still Need Anti‐IL2 Receptor Monoclonal Antibodies? , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[11] Ashesh P. Shah,et al. KDPI score is a strong predictor of future graft function: Moderate KDPI (35 - 85) and high KDPI (> 85) grafts yield similar graft function and survival . , 2016, Clinical Nephrology.
[12] S. R. Kim,et al. Waiting for a kidney transplant: the experience of patients with end-stage renal disease in South Korea. , 2016, Journal of clinical nursing.
[13] G. Martínez-Mier,et al. Induction Immunosuppressive Therapy Use in Deceased Donor Kidney Transplantation: 11-Year Experience in Veracruz, Mexico. , 2016, Transplantation proceedings.
[14] A. Wiseman. Induction Therapy in Renal Transplantation: Why? What Agent? What Dose? We May Never Know. , 2015, Clinical journal of the American Society of Nephrology : CJASN.
[15] I. Choi,et al. Comparison of the Clinical Outcomes between Anti-thymocyte Globulin and Basiliximab Induction Therapy in Deceased Donor Kidney Transplantation: Single Center Experience , 2015 .
[16] D. Brennan,et al. Selection of induction therapy in kidney transplantation , 2013, Transplant international : official journal of the European Society for Organ Transplantation.
[17] J. Joh,et al. Rabbit antithymocyte globulin compared with basiliximab in kidney transplantation: a single-center study. , 2012, Transplantation Proceedings.
[18] J. Lakey,et al. Induction therapy by anti-thymocyte globulin (rabbit) versus basiliximab in deceased donor renal transplants and the effect on delayed graft function and outcomes. , 2012, Transplantation proceedings.
[19] P. Reinke,et al. Long‐term outcome of ATG vs. Basiliximab induction , 2011, European journal of clinical investigation.
[20] P. Zhou,et al. Basiliximab or antithymocyte globulin for induction therapy in kidney transplantation: a meta-analysis. , 2010, Transplantation proceedings.
[21] Ethan M Balk,et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. , 2010, Kidney international.
[22] A. Webster,et al. Interleukin 2 receptor antagonists for kidney transplant recipients. , 2010, The Cochrane database of systematic reviews.
[23] J. Squifflet,et al. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. , 2009, Journal of the American Society of Nephrology : JASN.
[24] M. Schnitzler,et al. Early Outcomes of Thymoglobulin and Basiliximab Induction in Kidney Transplantation: Application of Statistical Approaches to Reduce Bias in Observational Comparisons , 2009, Transplantation.
[25] D. Brennan,et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. , 2006, The New England journal of medicine.